Stabilization of the disease as an important factor in the evaluation of the effectiveness of treatment and prognosis of survival for cancer patients


Cite item

Full Text

Abstract

Currently, the effectiveness of treatment is assessed by Response Evaluation Criteria In Solid Tumors (RECIST) criteria. The stabilization of the disease is the one of the results of the treatment. This term means a slight growth or regression of the tumor without the appearance of new lesions, when it is impossible to assign these changes neither to the progression of the disease nor to partial regression, but in any case stabilization of disease is evaluated as ineffective treatment. But the stabilization of the disease often leads to the improvement of the quality of life, slowdown in the growth of the tumor and metastasis and thereby to the win in terms of life expectancy. The purpose of the study. A study of the concept of ‘stabilization of the disease ’ as a criterion that determines the control of tumor growth. Methods. There was performed an analysis of various scientific works on the study of the efficiency of the treatment of solid tumors: ovarian cancer, small-cell lung cancer (SCLC), non small-cell lung cancer (NSCLC), colon cancer, prostate cancer, breast cancer. Conclusion. Stabilization of the disease is an important criterion for the evaluation of the antitumor treatment in patients and has the important prognostic value.

About the authors

Mark B. Bychkov

N.N. Blokhin Russian Cancer Research Center

Email: mbuchkov77@yandex.ru
MD, Phd, DSc, Prof., leading researcher of the Department of chemotherapy of the Research Institute of Clinical Oncology Moscow, 115478, Russian Federation

S. G Bagrova

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

T. D Karpenko

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

References

  1. Бычков М.Б. Стабилизация болезни, как фактор прогноза выживаемости после проведенной химиотерапии в онкологии. В кн.: Опыт доклинического исследования на примере олипифата. Санкт-Петербург; 2002: 273-4.
  2. Демина Е.А. Современные критерии оценки эффективности терапии больных злокачественными лифомами. Вместе против рака. Врачам всех специальностей. 2006; 2: 733-48.
  3. Therasse P. A Practical Guide to EORTC (European Organization for Research and Treatment of Cancer) Studies. Brussels: EORTC Data Center; 1996.
  4. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L. et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000; 92: 205-16.
  5. Therasse P: Measuring the clinical response. What does it mean? Eur. J. Cancer. 2002; 38: 1817-23.
  6. Переводчикова Н.И. Оценка лечебного действия противоопухолевых препаратов. В кн.: Руководство по химиотерапии опухолевых заболеваний. М.; 2005; т. 2: 28-32.
  7. Ferte С., Fernandez M., Hollebecque A., Koscielny S., Levy A., Massard C. et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin. Cancer Res. 2014; 20 (1): 246-52.
  8. Cesano A., Lane S.R., Poulin R., Ross G., Fields S.Z. Stabilisation of disease as an usefull predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patient. Int. J. Oncol. 1999; 15 (16): 1233-8.
  9. Cesano A., Lane S.R., Ross G.A., Fields S.Z. Stabilization of disease as an indicator of clinical benefit associated with chemotherapy in non-small cell lung cancer patients. Int. J. Oncol. 2000; 17: 587-90.
  10. Anderson J.R., Cain K.C., Gelber R.D. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J. Clin. Oncol. 2008; 26: 3913-5.
  11. Gronlund B., Hogdall C., Christensen I.J., Engelholm S.A., Hansen H.H. Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum? Gynecol. Oncol. 2004; 94: 409-15.
  12. He L., Teng Yu., Jin Bo, Zhao M., Yu P., Hu X. et al. Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer. BMC Cancer. 2010; 10: 681.
  13. Rapp E., Pater J.L., William A., Cormier Y., Murray N., Evans W.K. et al. Chemotherapy can prolong survival in patient with advanced non-small-cell lung cancer - report of Canadian multicenter randomized trial. J. Clin. Oncol. 1988; 6: 633-41.
  14. Graf W., Pahlman L., Bergstrom R., Glimelius B. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br. J. Cancer. 1994; 70: 559-63.
  15. Murphy G.P., Slack N.H. Response criteria of the prostate of the USA National Prostatic Cancer Project. Prostate. 1980; 1: 375-82.
  16. Howell A., Mackintosh J., Jones M., Redford J., Wagstaff J., Sellwood R.A. The definition of the «no change» category in patient treated with endocrine therapy and chemotherapy for advanced carcinoma of the brest. Eur. J. Cancer Clin. Oncol. 1988; 24: 1567-72.

Copyright (c) 2016 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies